These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21714003)

  • 21. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
    Kalinderi K; Fidani L; Bostantjopoulou S; Katsarou Z; Kotsis A
    Eur J Neurol; 2007 Oct; 14(10):1088-90. PubMed ID: 17880562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease.
    Haubenberger D; Bonelli S; Hotzy C; Leitner P; Lichtner P; Samal D; Katzenschlager R; Djamshidian A; Brücke T; Steffelbauer M; Bancher C; Grossmann J; Ransmayr G; Strom TM; Meitinger T; Gasser T; Auff E; Zimprich A
    Mov Disord; 2007 Aug; 22(11):1640-3. PubMed ID: 17523199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
    Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
    Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
    Hernandez DG; Paisán-Ruíz C; McInerney-Leo A; Jain S; Meyer-Lindenberg A; Evans EW; Berman KF; Johnson J; Auburger G; Schäffer AA; Lopez GJ; Nussbaum RL; Singleton AB
    Ann Neurol; 2005 Mar; 57(3):453-6. PubMed ID: 15732108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical heterogeneity of the LRRK2 G2019S mutation.
    Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
    Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease.
    Squillaro T; Cambi F; Ciacci G; Rossi S; Ulivelli M; Malandrini A; Mencarelli MA; Mari F; Renieri A; Ariani F
    J Hum Genet; 2007; 52(3):201-204. PubMed ID: 17235449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
    Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
    Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins.
    Munhoz RP; Wakutani Y; Marras C; Teive HA; Raskin S; Werneck LC; Moreno D; Sato C; Lang AE; Rogaeva E
    Mov Disord; 2008 Jan; 23(2):290-4. PubMed ID: 17999435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
    Elbaz A
    Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536
    [No Abstract]   [Full Text] [Related]  

  • 34. LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease.
    Patra B; Parsian AJ; Racette BA; Zhao JH; Perlmutter JS; Parsian A
    Parkinsonism Relat Disord; 2009 Mar; 15(3):175-80. PubMed ID: 18752982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.
    Lohmann E; Leclere L; De Anna F; Lesage S; Dubois B; Agid Y; Dürr A; Brice A;
    Parkinsonism Relat Disord; 2009 May; 15(4):273-6. PubMed ID: 18718805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LRRK2 G2019S mutations may be increased in Puerto Ricans.
    Saunders-Pullman R; Cabassa J; San Luciano M; Stanley K; Raymond D; Ozelius LJ; Bressman SB
    Mov Disord; 2011 Aug; 26(9):1772-3. PubMed ID: 21449009
    [No Abstract]   [Full Text] [Related]  

  • 37. LRRK2 mutations in Basque patients with Parkinson's disease.
    Zarranz JJ; Gómez-Esteban JC
    Lancet Neurol; 2008 Oct; 7(10):866-7; author reply 867. PubMed ID: 18848304
    [No Abstract]   [Full Text] [Related]  

  • 38. Is the G2019S LRRK2 mutation common in all southern European populations?
    Papapetropoulos S; Adi N; Shehadeh L; Bishopric N; Singer C; Argyriou AA; Chroni E
    J Clin Neurosci; 2008 Sep; 15(9):1027-30. PubMed ID: 18617409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain).
    Sierra M; González-Aramburu I; Sánchez-Juan P; Sánchez-Quintana C; Polo JM; Berciano J; Combarros O; Infante J
    Mov Disord; 2011 Nov; 26(13):2343-6. PubMed ID: 21954089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRRK2-G2019S mutation is not associated with an increased cancer risk: a kin-cohort study.
    Allegra R; Tunesi S; Cilia R; Pezzoli G; Goldwurm S
    Mov Disord; 2014 Sep; 29(10):1325-6. PubMed ID: 25048644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.